NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board

Reuters11-06

NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board

NewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581206295?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581206295","market":"us","top_or_hot":-1,"title":"NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NCEL\">NewcelX Ltd.</a> has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a>'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NCEL\">NewcelX Ltd.</a> has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with <a href=\"https://laohu8.com/S/NLSP\">NLS Pharmaceutics Ltd.</a>'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6VHvTG:1","article_id":"2581206295","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581206295","pubTimestamp":1762430625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4139":"生物科技","NCEL":"NewcelX Ltd.","NLSP":"NLS Pharmaceutics Ltd."},"translate_title":"NLS Pharmaceutics任命Tamir Ben-Hur教授为NewcelX科学顾问委员会成员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NCEL":0.9,"NLSP":0.9},"content_text":"NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board\n    \n\nNewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO17614) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581206295","isCrawlerRequest":true}